Simpson Thacher is representing Certara, Inc. (Nasdaq: CERT) in its announced definitive agreement to acquire Pinnacle 21 for $310 million in cash and stock. The transaction is expected to close in the fourth quarter of 2021 and is subject to customary regulatory approvals and other closing conditions.
Pinnacle 21 is a global leader in software for preparing clinical trial data for regulatory submission. Its platform validates data quality and compliance with CDISC standards, enabling a clean data pipeline from worldwide sponsors to health authorities, including the FDA, PMDA and NMPA. Streamlined approvals bring life-saving medicines to patients faster.
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
The Simpson Thacher team includes: Michael T. Holick, Fred de Albuquerque, Kira Shannahan, Paul Clatterbuck and Jessica Mason (M&A); David Rubinsky, Caitlin Lucey and Allison Sutherland (Employee Benefits and Executive Compensation); Jonathan Goldstein and Jasmine Hay (Tax); Genevieve Dorment, Kate Mirino and Samuel Watters (Intellectual Property); and Vanessa K. Burrows (Healthcare).